Drug Trial Radar · NCT00806819
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Last checked: Nov 20, 2026Latest source record: Feb 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
718
Actual
Start
Dec 2008
Primary completion
Jun 2011
Study completion Dec 2015
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Dec 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120)Drug
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
PemetrexedDrug
500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
pemetrexedDrug
500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
B12Drug
1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
dexamethasone (or corticosteroid equivalent)Drug
4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
placeboDrug
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
dexamethasone (or corticosteroid equivalent)Drug
4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
B12Drug
1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
Folic AcidDrug
400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
B12Drug
1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
dexamethasone (or corticosteroid equivalent)Drug
4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
Folic AcidDrug
400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
placeboDrug
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Folic AcidDrug
400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
Nintedanib (BIBF1120)Drug
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
PemetrexedDrug
500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by Central Independent ReviewTime frame: From randomisation until cut-off date 9 July 2012
Locations
163 sites in 32 countries. Site status is shown where the registry gives one.
Boehringer Ingelheim Investigational Site
Downy, California
Boehringer Ingelheim Investigational Site
Fountain Valley, California
Boehringer Ingelheim Investigational Site
Fullerton, California
Boehringer Ingelheim Investigational Site
Long Beach, California
Boehringer Ingelheim Investigational Site
Meriden, Connecticut
Boehringer Ingelheim Investigational Site
Aventura, Florida
Boehringer Ingelheim Investigational Site
Boynton Beach, Florida
Boehringer Ingelheim Investigational Site
Jacksonville, Florida
Boehringer Ingelheim Investigational Site
Miami, Florida
Boehringer Ingelheim Investigational Site
New Port Richey, Florida
Boehringer Ingelheim Investigational Site
Port Saint Lucie, Florida
Boehringer Ingelheim Investigational Site
Stuart, Florida
Boehringer Ingelheim Investigational Site
Galesburg, Illinois
Boehringer Ingelheim Investigational Site
Skokie, Illinois
Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
Boehringer Ingelheim Investigational Site
New Albany, Indiana
Boehringer Ingelheim Investigational Site
Witchita, Kansas
Boehringer Ingelheim Investigational Site
Ashland, Kentucky
Boehringer Ingelheim Investigational Site
Louisville, Kentucky
Boehringer Ingelheim Investigational Site
Burlington, Massachusetts
Boehringer Ingelheim Investigational Site
Springfield, Massachusetts
Boehringer Ingelheim Investigational Site
Saint Louis Park, Minnesota
Boehringer Ingelheim Investigational Site
Grand Island, Nebraska
Boehringer Ingelheim Investigational Site
Farmington, New Mexico
Boehringer Ingelheim Investigational Site
Dunkirk, New York
Boehringer Ingelheim Investigational Site
Goshen, New York
Boehringer Ingelheim Investigational Site
Lake Success, New York
Boehringer Ingelheim Investigational Site
Nyack, New York
Boehringer Ingelheim Investigational Site
Asheville, North Carolina
Boehringer Ingelheim Investigational Site
Canton, Ohio
Boehringer Ingelheim Investigational Site
Sandusky, Ohio
Boehringer Ingelheim Investigational Site
Ephrata, Pennsylvania
Boehringer Ingelheim Investigational Site
Langhorne, Pennsylvania
Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
Boehringer Ingelheim Investigational Site
Germantown, Tennessee
Boehringer Ingelheim Investigational Site
Amarillo, Texas
Boehringer Ingelheim Investigational Site
Seattle, Washington
Boehringer Ingelheim Investigational Site
Spokane, Washington
Boehringer Ingelheim Investigational Site
Madison, Wisconsin
Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.